Danaher completed the acquisition of biopharma business of General Electric for $21bn.

Danaher, a global science and technology innovator, completed the acquisition of the biopharma business of General Electric, an American multinational conglomerate, for $21bn. “Completing the sale of BioPharma represents a critical milestone on our multi-year transformation, fortifying our considerable sources to de-risk our balance sheet and continue to solidify our financial position. I am proud of the teams for completing this transaction amidst a great deal of global change," H. Lawrence Culp, GE Chairman and CEO.